L3VLUP
ProSign in

DNLI in the 13F filings

Denali Therapeutics Inc · CUSIP 24823R105

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q3 2026 · early filersQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Q3 2026: 5 of 95 managers have filed so far; the filing deadline is 16 November 2026. Its figures cover those filers only, so it is not yet a picture of the tracked managers.

Quarter end
30 Sep 2026
the date the book describes
Filed
9 Nov 2026
latest of these filings; the earliest 9 Nov 2026
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
5
filed both Q2 2026 and Q3 2026; 1 listed it in both
Shares listed
11,165,279
combined, among listed positions
Reported value
$231m
combined, at the quarter end

Among the 5 comparable managers: 2 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares was -801,427.

Managers listing DNLI in Q3 2026

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2026, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Baillie Gifford & Co11,119,945$230m0.22%Trimmed-840,2859 Nov 2026 (the filing on sec.gov)
Squarepoint Ops LLC33,534$693kunder 0.1%Newnew9 Nov 2026 (the filing on sec.gov)
Acadian Asset Management LLC11,800$242kunder 0.1%Added+5,3249 Nov 2026 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2026 to Q3 2026, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
6 in Q4 2024 to 1 in Q3 2026

Tracked managers listing it, at least.

035810201820192020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
DNLI by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20172$78mn.a.n.a.
Q1 20181$102mn.a.n.a.
Q2 20181$82mn.a.n.a.
Q3 20182$122mn.a.n.a.
Q4 20182$131mn.a.n.a.
Q1 20192$146mn.a.n.a.
Q2 20192$154mn.a.n.a.
Q3 20192$113mn.a.n.a.
Q4 20192$133mn.a.n.a.
Q1 20203$165mn.a.n.a.
Q2 20202$226mn.a.n.a.
Q3 20204$406mn.a.n.a.
Q4 20207$1.6bnn.a.n.a.
Q1 20217$1.2bnn.a.n.a.
Q2 20215$1.7bnn.a.n.a.
Q3 20216$1.1bnn.a.n.a.
Q4 20214$709mn.a.n.a.
Q1 20223$507mn.a.n.a.
Q2 20225$481mn.a.n.a.
Q3 20228$629mn.a.n.a.
Q4 20226$766mn.a.n.a.
Q1 20234$423mn.a.n.a.
Q2 20236$760mn.a.n.a.
Q3 20235$539mn.a.n.a.
Q4 20238$577m44
Q1 20249$669m72
Q2 20249$829m53
Q3 20247$1.1bn44
Q4 20246$625m15
Q1 20255$422m23
Q2 20254$270m23
Q3 20255$333m41
Q4 20256$342m1515
Q1 20267$372m1316
Q2 20265$514m1312
Q3 20261$230m21

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

DNLI and GILD →DNLI and AMGN →DNLI and ARGX →Choose a stock to compare with DNLI →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own DNLI, latest filings →Back to the 13F Explorer →